<DOC>
	<DOCNO>NCT01745744</DOCNO>
	<brief_summary>Clinical trial phase I / II , prospective , multicenter , open , randomize , parallel-groups control two level dose assess safety feasibility infusion mesenchymal stem cell adipose tissue administer intra-arterially nondiabetic patient chronic ischemia low limb ( CLI ) possibility revascularization .</brief_summary>
	<brief_title>Application Cell Regeneration Therapy With Mesenchymal Stem Cells From Adipose Tissue Critical Chronic Ischemic Syndrome Lower Limbs ( CLI ) Nondiabetic Patients .</brief_title>
	<detailed_description>A prospective , multicenter , open , randomize , parallel-group control study two level dose . The study population consist 30 non-diabetic patient critical chronic ischemia least one low limb ( CLI ) without possibility revascularization , result clinically evaluable , , 20 patient include experimental group ( 10 dose level ) 10 control group . In two dose level use study , 15 patient include , randomize experimental group control group accord distribution 2:1 ( 2 patient experimental group 1 control group ) , thus dose level , 10 patient experimental group ( treat mesenchymal cell adipose tissue ) 5 patient control group ( conventional treatment , include use prostaglandin per protocol ) . Patients randomized experimental treatment Group CeTMAd may receive one follow dose level : - 0.5x106 cell / kg patient weight - 1x106 cell / kg patient weight The recruitment do escalate dos , start low dose . To switch high dose require favorable opinion Ethics Committee H. Universitario Virgen Macarena evaluate clinical status patient therapeutic safety study procedure . Patients randomized treatment control group continue conventional treatment perform time inclusion study ( include use prostaglandin protocol ) . STUDY OBJECTIVE : To evaluate safety feasibility regenerative treatment mesenchymal stem cell adipose tissue ( CeTMAd ) , administer intraarterial nondiabetic patient chronic critical ischemia least one low limb without possibility revascularization alternative therapy . We analyze complication regenerative therapy / study procedure . - Main objective : 1 . Security : It study possible complication due procedure first 24 hour administration CeTMAd , 1 month , 3 month , 6 month , 9 month 12 month . 2 . Efficiency : It study generation new vessel ( vasculogenesis ) enhancement collateral circulation ( angiogenesis / arteriogenesis ) . - Secondary objective : It study evolution ankle brachial index , transcutaneous oxygen pressure , degree Rutherford-Becker , ulcer size , calf perimeter , score pain intermittent claudication ( walk test ) . Duration clinical trial : From infusion patient Mesenchymal Stem Cells Adipose Tissue end monitoring , 12 month .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Patients sex age ≥ 18 ≤ 89 year . Nondiabetic . Infrapopliteal atherosclerotic vascular disease severe grade either severe claudication RutherfordBecker grade IIIIIIV , least one low limb . It define critical ischemia lower limb persistent/recurrent pain require analgesia / nonhealing present ulcer &gt; 4 week , evidence improvement conventional therapy / walk test ( stress test ) 16 minute two exercise test separate least 2 week / anklebrachial index rest &lt; 0.8 . Inability surgical endovascular revascularization recommend TransAtlantic InterSociety Consensus ( TASC ) . Failure revascularization surgery perform least 30 day , persistence entry critical ischemia phase . Life expectancy &gt; 2 year . Not expect major amputation limb treat next 12 month inclusion . Normal biochemical parameter define : 1 . Leukocytes ≥ 3000 2 . Neutrophils ≥ 1500 3 . Platelets ≥ 100,000 4 . Aspartate aminotransferase ( AST ) / Alanine aminotransferase ( ALT ) ≤ 2.5 standard range institution 5 . Creatinine ≤ 2.5 mg / dl . Patients give write informed consent participate study . Women childbearing potential must negative result pregnancy test do time inclusion study agree use medically approve method contraception duration study . History malignancy hematologic disease ( myeloproliferative disease , myelodysplastic syndrome leukemia ) last two year . Patients uncontrolled hypertension ( define blood pressure &gt; 180/110 one occasion ) . Severe heart failure ( New York Heart Association class IV ) ejection fraction leave ventricle le 30 % . Patients malignant ventricular arrhythmia unstable angina time infusion . Diagnosis deep vein thrombosis previous 3 month . Active infection wet gangrene day infusion Mesenchymal Stem Cells Adipose Tissue . Concomitant therapy include hyperbaric oxygen . It allow use antiplatelet agent . Body mass index &gt; 40 kg/m2 . Patients diagnosis alcoholism time inclusion . Untreated proliferative retinopathy . Concomitant disease reduce life expectancy less year . Predicted impossibility obtain biopsy provide 10 g adipose tissue . human immunodeficiency virus , hepatitis B virus hepatitis C virus . Difficulty monitoring . Stroke myocardial infarction within last 3 month . Anemia ( hemoglobin &lt; 7.9 mg / dl ) . Leukopenia . Thrombocytopenia ( &lt; 100,000 platelet / ul ) . Pregnant woman woman childbearing age adequate contraception . Patients participate clinical trial within last 3 month prior inclusion clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>